1 **Pathway-based Rare Variant Burden Analysis Identifies a Role for the Complement System in an** 2 **Extreme Phenotype of Sepsis with Coagulopathy**

3 Pavan K. Bendapudi^{1,2,3}, Sumaiya Nazeen^{3,4}, Justine Ryu^{1,3}, Onuralp Söylemez^{3,4}, Betty Rouaisnel⁵,
4 Meaghan Colling^{2,3}, Bryce Pasko⁶, Alissa Robbins⁷, Michael Bouzinier^{3,4}, Lindsay Tomczak¹, Lindsay
5 Collier¹, Sanjay Ram⁸, Agnes Toth-Petroczy^{3,4}, Joel Krier^{3,4}, Elizabeth Fieg⁴, Walter H. Dzik^{2,3}, James
6 C. Hudspeth^{9,10}, Olga Pozdnyakova^{3,11}, Valentina Nardi^{3,12}, Richard Maas^{3,4}, Shamil Sunyaev^{3,4}, Julie-
7 Aurore Losman^{3,5,13*}

8 ¹Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Boston, MA; ²Division
9 of Hematology and Blood Transfusion Service, Massachusetts General Hospital, Boston, MA; ³Harvard
10 Medical School, Boston, MA; ⁴Division of Genomic Medicine, Brigham and Women's Hospital, Boston,
11 MA; ⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; ⁶Department of
12 Pathology, University of Colorado School of Medicine; ⁷Immunology Division, Walter and Eliza Hall
13 Institute of Medical Research, Melbourne, Australia; ⁸Division of Infectious Diseases and Immunology,
14 University of Massachusetts Medical School, Worcester, MA; ⁹Department of Medicine, Boston
15 Medical Center, Boston, MA; ¹⁰Boston University School of Medicine, Boston, MA; ¹¹Department of
16 Pathology, Brigham and Women's Hospital, Boston, MA; ¹²Department of Pathology, Massachusetts
17 General Hospital, Boston, MA; ¹³Division of Hematology, Brigham and Women's Hospital, Boston,
18 MA

19 *Email of corresponding author: julieaurore_losman@dfci.harvard.edu

20 **Extreme disease phenotypes have the potential to provide key pathophysiologic insights, but the**
 21 **study of these conditions is challenging due to their rarity and the limited statistical power of**
 22 **existing methods. Herein, we apply a novel pathway-based approach to investigate the role of rare**
 23 **genomic variants in infectious purpura fulminans (PF)^{1,2}, an extreme phenotype of sepsis with**
 24 **hyperinflammation and coagulopathy for which the role of inherited risk factors is currently**
 25 **unknown. Using whole exome sequencing, we found a significantly increased burden of rare,**
 26 **putatively function-altering coding variants in the complement system in patients with PF**
 27 **compared to unselected patients with sepsis (p -value = 0.01). Functional characterization of a**
 28 **subset of PF-associated variants in integrin complement receptors 3 and 4 (CR3 and CR4) revealed**
 29 **that they exhibit a pro-inflammatory phenotype. Our results suggest that rare inherited defects**
 30 **in the complement system predispose individuals to the maladaptive hyperinflammatory response**
 31 **that characterizes severe sepsis.**

32 Rare coding variants are instrumental in identifying genes and pathways involved in disease biology.
 33 However, analyses of rare variants using traditional single-variant and single-gene association tests often
 34 fail even with large sample sizes³, and the assembly of patient cohorts with uncommon diseases presents
 35 an additional challenge. Two strategies can overcome these barriers: (i) conducting extreme phenotype
 36 studies (EPS) to amplify the effects of rare variants²¹⁻²⁴, and (ii) leveraging prior biological knowledge
 37 by applying collapsing tests at the level of pathways in which multiple genes function together with
 38 directionally consistent effects⁴⁻⁶.

39 In sepsis, dysregulation of the host response to infection causes harmful levels of systemic inflammation,
 40 leading to end-organ damage⁷. The clinical acuity of sepsis varies dramatically, and it is currently
 41 impossible to predict which patients will experience a severe disease course. Attempts to identify genetic
 42 factors underlying the risk for sepsis have been limited to small genome wide association studies
 43 (GWAS)⁸⁻¹¹ and a single whole exome sequencing study of 74 patients¹². However, due to the

heterogeneity of the patient population, the lack of a narrowly defined clinical phenotype, the diversity of pathogens involved in sepsis, and the inherent limitations of GWAS, these efforts have been largely inconclusive. A well-designed EPS focusing on pathways that could plausibly contribute to disease pathophysiology has the potential to overcome these challenges and elucidate novel biology that is generalizable to the broader population of septic patients.

To identify genetic risk factors for severe sepsis, we undertook a case-controlled EPS of the complement system in infectious PF, an exceptionally rare and devastating extreme sepsis phenotype¹. The defining feature of PF is uncontrolled systemic inflammation and thrombotic coagulopathy resulting in microvascular thrombosis, end-organ damage, and death. Mortality is as high as 80%, and survivors typically experience extensive scarring and dismemberment^{1,2,13}. The complement system (**Figure 1A**), which is responsible for the initial inflammatory response to infection, has long been considered a key driver of inflammation in severe sepsis and PF¹⁴⁻¹⁷. Microbes directly activate the humoral complement cascade, a tightly-regulated series of proteolytic reactions that result in pathogen destruction by the membrane attack complex (MAC) and release of highly inflammatory microbial cell components. Activated complement proteins also function as potent inflammatory mediators (anaphylatoxins) that promote shock and other features of sepsis. During this process, the complement fragment C3b is deposited on microbial surfaces, where it is converted to iC3b, a potent opsonin that binds integrin complement receptors CR3 and CR4 on macrophages^{18,19}. This leads to phagocytosis of microbes and activation of immunomodulatory signaling. Integrins are each composed of an α and a β subunit, different combinations of which give rise to receptors with distinct physiologic roles. CR3 ($\alpha_M\beta_2$) is composed of integrin β_2 (*ITGB2*) paired with integrin α_M (*ITGAM*), whereas CR4 ($\alpha_X\beta_2$) is composed of integrin β_2 paired with integrin α_X (*ITGAX*). Intracellular signaling via CR3 promotes an anti-inflammatory and immunoregulatory cytokine profile, whereas CR4 signaling promotes a pro-inflammatory state (**Figure 1B**)²⁰⁻²². Given that inflammation stemming from infection is strongly

68 associated with aberrant activation of coagulation²³⁻²⁵, we reasoned that rare function-altering mutations
69 in the complement system could plausibly contribute to the pathophysiology of PF.

70 To assemble a sequencing cohort of patients with this rare, highly lethal condition, we combined
71 prospective sample collection with a unique automated “look back” approach in which we leveraged
72 natural language processing to perform enterprise-scale deep mining of the electronic medical record
73 system to identify historical cases of PF. Using this technique, we were able to locate archived pathology
74 specimens suitable for germline sequencing from PF patients who were deceased or lost to follow up.
75 In total, we identified 40 clinically well-annotated PF patient samples and, as controls, utilized 87
76 unselected patients with sepsis from the NHLBI ARDSnet iSPAAR consortium ([Supplementary Tables](#)
77 [1 and 2](#)). Whole exome sequencing data from all 127 samples were jointly called using the GATK
78 pipeline v3.5. After performing variant-level and sample-level quality control (QC), we removed three
79 PF patient samples ([Supplementary Figure 1](#)). In the remaining specimens, we analyzed qualifying
80 variants in the complement system with a gnomAD global minor allele frequency (MAF) of < 0.05 as
81 well as those with an optimal in-cohort frequency cutoff selected using a variable thresholds (VT)
82 approach²⁶. Missense variants predicted to be “deleterious” or “possibly deleterious” by either
83 PolyPhen2 or SIFT were grouped with high-precision loss of function (LoF) variants (stop gained, stop
84 lost, splice donor, splice acceptor, splice region variant, and frameshift and in-frame indel) and together
85 were termed “ΔP variants.”

86 Interrogating the effects of rare variants in a pathway using an EPS design requires addressing two issues.
87 Firstly, population structure can inflate the false positive rate in both the common and rare variant
88 space²⁷. This issue can be mitigated by analyzing EPS cohorts of a single ancestry. Secondly, existing
89 pathway-based collapsing approaches frequently focus only on the presence or absence of rare variants
90 and are of limited value because many individuals will have at least one rare variant in a large pathway.

91 This challenge necessitates a new test that focuses on the number of qualifying rare variants rather than
92 simply their presence or absence.

93 To assess population structure, we performed principal component analysis (PCA) on the study samples
94 (**Supplementary Figure 2**). We found that all 87 sepsis controls but only 24/37 PF patients were of
95 European descent, and we therefore limited our primary analysis to individuals of European ancestry.
96 To rule out the possibility that other unrecognized population structures could introduce bias into our
97 analysis, we evaluated the distribution of ultra-rare (i.e., doubletons and tripletons) missense and
98 synonymous variants shared between the 24 European PF cases and 87 controls and observed no
99 significant differences (**Supplementary Table 3**).

100 Across the entire Boston PF Cohort (N=37), we identified a total of 58 unique missense variants in the
101 complement system (N = 27 autosomal genes) (**Supplementary Table 4**) with MAF < 0.05, of which
102 42 were present only in the PF cohort and 16 were present in both the PF and control cohorts (**Table 1**
103 **and Supplementary Tables 5 and 6**). Of these, 32 (55.2%) were annotated as functionally significant
104 *in silico*. We also found 26 high-precision LoF variants. Of these, 22 were specific to PF patients and 4
105 were found in both PF and control patients. In total, 58 unique ΔP variants were identified in PF patients.
106 In the control cohort of unselected patients with sepsis (N=87), we identified a total of 68 unique rare
107 missense variants, of which 52 were present only among the controls and 16 were present in both cohorts.
108 Of these, 39/68 (57.3%) were putatively function altering. The control cohort also contained 15 high-
109 precision LoF variants, for a total of 54 ΔP variants. Of note, inclusion of non-European PF patients
110 increased the burden of rare ΔP variants when compared to the European-only PF patient cohort
111 (**Supplementary Figure 3**), which suggests that PF patients have an increased proportion of rare ΔP
112 variants in the complement system regardless of ethnic background. However, we cannot validate this
113 conclusion without a control cohort having the same population structure.

114 To determine whether ΔP variants are enriched in PF patients, we devised a novel rare variant trend test
 115 (RVTT) utilizing the Cochran-Armitage statistic to assess the relationship between complement system
 116 variant burden and disease status^{28,29}. We performed RVTT on the European PF patients (N=24) and
 117 sepsis controls (N=87) using a fixed gnomAD MAF cutoff of 0.05 as well as a variable thresholds
 118 approach with or without an in-cohort MAF cutoff. We observed a significant linear trend in the number
 119 of complement system ΔP variants in the PF patients compared to controls (gnomAD cutoff: permutation
 120 p-value = 0.0168, z-score = 2.5; VT approach with MAF cutoff up to 0.05: permutation p-value = 0.0134,
 121 z-score = 2.62; VT approach without cutoff: p-value = 0.0278, z-score = 2.72) (**Table 2, Figure 1C**).
 122 To determine whether the association of ΔP variants with PF was independent of clinical and
 123 demographic parameters, we generated a multivariate logistic regression model incorporating age, sex,
 124 and Sequential Organ Failure Assessment (SOFA) score, a validated composite measure of illness
 125 severity in critical care patients that encompasses 8 distinct clinical criteria³⁰. After adjusting for these
 126 co-variables, we found that the number of ΔP variants per subject independently predicted PF in the
 127 patients of European ancestry (OR=2.61 per ΔP variant, 95% CI: 1.29-6.1, P=0.01) (**Table 3**). Including
 128 all patients in the analysis yielded a similar result. This finding suggests that multiple ΔP variants in a
 129 single patient contribute to the development of PF and orthogonally confirms the association found using
 130 RVTT.

131 Notably, a simple one-sided collapse and combine (CMC) Fisher's exact test of ΔP variants in the
 132 complement system at a gnomAD global MAF cutoff of 0.05 was borderline significant (p-value:
 133 0.0418) (**Supplementary Table 7**), and when we performed gene-based collapsing analyses using the
 134 CMC-Fisher³¹, VT-Price²⁶, KBAC³², and SKAT³³ tests, none of the genes in the complement system
 135 individually showed a significant enrichment of rare ΔP variants in PF cases after Bonferroni correction
 136 (**Supplementary Table 8**). This result further supports our approach of performing a pathway-based
 137 collapsing analysis that leverages prior biological knowledge. Finally, to rule out the possibility that the

138 observed ΔP RVTT signal resulted from a technical artifact, we repeated RVTT with synonymous and
 139 predicted functionally neutral missense variants in the complement pathway and observed no significant
 140 linear trend (**Table 2, Figure 1C**). To further ensure the validity of our findings, we also performed
 141 RVTT on two additional gene sets: (i) the coagulation system, a distinct pathway that could plausibly be
 142 implicated in PF, and (ii) glycolysis, an unrelated pathway (**Supplementary Table 4**). Neither gene set
 143 demonstrated an enrichment in ΔP variants in the PF cohort (**Table 2, Figure 1D**).

144 Of the 58 unique ΔP variants identified in PF patients, 15 (25.9%) were found in genes encoding subunits
 145 of CR3 and CR4. Given the dearth of functional data on these variants and their high frequency in PF
 146 patients, we cloned all 11 *ITGB2*, *ITGAM*, and *ITGAX* variants found in the Boston PF cohort
 147 (**Supplementary Figure 4**) and characterized the resultant CR3 and CR4 receptors. We found that
 148 intracellular expression levels of all the cloned variants were similar (**Supplementary Figure 5**).
 149 However, cell-surface expression of the CR3 variants was significantly lower than that of wild-type CR3
 150 (**Figure 2A**), whereas cell-surface expression of the CR4 variants was similar to that of wild-type CR4
 151 (**Figure 2B**). Notably, the D283N mutation in the shared β_2 subunit resulted in complete loss of CR3
 152 surface expression without affecting the surface level of CR4. We also assessed binding of the variants
 153 to iC3b. Of the CR3 variants, 6/8 (75%) demonstrated significantly reduced binding to iC3b compared
 154 to wild-type CR3 (**Figure 2C**). By contrast, 4/7 (57.1%) CR4 variants showed similar iC3b binding to
 155 wild-type and, unexpectedly, 3/7 (42.9%) demonstrated increased binding compared to wild-type CR4
 156 (**Figure 2D**). Given that the mutant CR4 lines all expressed equivalent or slightly reduced surface levels
 157 compared to wild-type, the observed increase in iC3b binding to specific CR4 mutants likely reflects an
 158 increased affinity of those mutants for iC3b. Finally, we used a dual-luciferase reporter assay to assess
 159 the impact of the PF-associated CR3 and CR4 variants on TNF α -mediated activation of the canonical
 160 pro-inflammatory transcription factor NF- κ B. Relative to untransfected control cells, NF- κ B activation
 161 was suppressed by expression of wild-type CR3 and was enhanced by expression of wild-type CR4

(Figure 3A). The 7 expressed CR3 variants were associated with increased activation of NF- κ B compared to wild-type CR3. 6/7 (85.7%) CR4 variants showed increased NF- κ B activation compared to wild-type CR4. Taken together, these findings suggest that PF-associated CR3/4 variants result in a relative loss of anti-inflammatory CR3 function and a relative gain of pro-inflammatory CR4 function.

In summary, we applied RVTT, a new pathway-based mutational burden analysis approach, to an EPS of sepsis and demonstrated a relationship between rare, putatively function-altering complement system variants and the development of infectious PF. Functional characterization of PF-associated complement receptor variants identified mutations that result in loss of anti-inflammatory signaling (Figure 3B) or gain of pro-inflammatory signaling (Figure 3C), consistent with the phenotype of severe sepsis with coagulopathy³⁴. We also identified several examples of single mutations in the shared complement receptor subunit integrin β_2 that simultaneously enhance pro-inflammatory signaling and abrogate anti-inflammatory signaling (Figure 3D), a novel finding in complement receptor biology. Our genetic and functional studies support a model in which PF is driven by a genetically-encoded maladaptive inflammatory response to infection, findings that will help to risk-stratify patients with sepsis and inform the development of novel strategies to treat the thrombo-inflammatory complications of severe infection. This study also serves as a model for leveraging known biological pathways to gain insights into the genetics of extreme phenotypes and rare conditions.

Several questions remain that warrant further investigation. Firstly, due to the limited availability of clinical cases, we were unable to analyze the roles of specific microbes in the pathogenesis of PF. Secondly, our approach cannot rule out that other, as yet unidentified, genetic modifiers influence the predisposition to PF. Despite these limitations, this study represents an important step forward in defining the genetic determinants of severe sepsis.

184 **Table 1: Complement system variants found in the study cohorts.** The number and types of
185 complement system variants identified in the Boston PF cohort (PF) (N = 37) and the NHLBI ARDSnet
186 iSPAAR Unselected Sepsis (US) cohort (N = 87).

	Total PF-associated variants	Total US associated-variants	PF-specific variants	US-specific variants	Shared variants
Neutral	26	29	16	19	10
Missense	58	68	42	52	16
Missense ^F	32	39	26	33	6
HP LoF	26	15	22	11	4
ΔP variants	58	54	48	44	10

187 Missense^F = missense variants predicted *in silico* to cause altered protein function

188 HP LoF = high-precision loss-of-function

189 ΔP variants = Missense^F + HP LoF

190 **Table 2. Rare variant burden assessed by Rare Variant Trend Test (RVTT) in quality-filtered**
 191 **European PF cases (N=24) and sepsis controls (N=87).** We applied RVTT on three gene sets: the
 192 complement system, the coagulation system, and the glycolysis pathway. For each gene set, we tested
 193 rare ΔP , synonymous, and neutral missense variants. Qualifying rare variants were selected using three
 194 settings: (i) fixed threshold: gnomAD MAF < 0.05, (ii) variable threshold with no cutoff, and (iii)
 195 variable threshold with a cutoff of MAF = 0.05. We observed a significant enrichment of rare ΔP variants
 196 in the complement system under all three settings.

Type	RVTT-Fixed Test Statistic (gnomAD cutoff)	RVTT-Fixed Perm p-value (gnomAD cutoff)	RVTT-Variable Selected Threshold (No Cutoff)	RVTT-Variable Test Statistic (No Cutoff)	RVTT-Variable Perm p-value (No Cutoff)	RVTT-Variable Selected Threshold (cutoff = 0.05)	RVTT-Variable Test Statistic (cutoff = 0.05)	RVTT-Variable Perm p-value (cutoff = 0.05)
Complement System Pathway								
ΔP variants	2.4951	0.0168	0.0833	2.7229	0.0278	0.0463	2.6236	0.0134
Synonymous	1.5071	0.1368	0.25	1.1308	0.8166	0.0463	1.0267	0.4438
Neutral missense	1.0195	0.323	0.3704	1.0636	0.8954	0.0463	0.7881	0.7237
Coagulation Pathway								
ΔP variants	1.3329	0.1866	0.015	0.9856	0.5718	0.0114	0.9856	0.6519
Synonymous	1.68	0.0996	0.205	1.4318	0.3251	0.0114	1.2291	0.4873
Neutral missense	0.7912	0.4864	0.068	1.3924	0.4095	0.0265	0.8997	0.7392
Glycolysis Pathway								
ΔP variants	0.0536	0.9563	0.035	1.0827	0.5804	0.0315	1.0827	0.5265
Synonymous	0.1035	0.9256	0.185	1.4843	0.309	0.0079	0.8554	0.7307
Neutral missense	0.3942	0.7607	0.169	1.8254	0.2089	0.0118	0.6315	0.7491

197 **Table 3: Multivariate logistic regression model of predictors of purpura fulminans.**

EUR Only Analysis (N=111)				
	β	SE	OR (95% CI)	P value
ΔP variants	0.96	0.39	2.61 (1.29-6.1)*	0.01
Sex	-1.58	0.93	0.21 (0.03-1.18)	0.09
Age	-0.05	0.02	0.95 (0.91-0.99) [†]	0.02
SOFA Score ^{††}	0.67	0.16	1.96 (1.49-2.87) ^{†††}	<0.0001
Entire Study Analysis (N=124)				
	β	SE	OR (95% CI)	P value
ΔP variants	1.05	0.33	2.85 (1.58-5.90)*	0.002
Sex	-1.02	0.81	0.36 (0.07-1.72)	0.21
Age	-0.06	0.02	0.94 (0.90-0.98) [†]	0.005
SOFA Score ^{††}	0.75	0.17	2.12 (1.59-3.16) ^{†††}	<0.0001

198 * Per ΔP variant

199 [†]Per year of age

200 ^{††}Composite measure comprised of: PaO₂, FiO₂, mechanical ventilation status, platelet count, Glasgow
 201 Coma Scale, total bilirubin level, mean arterial pressure, and creatinine level.

202 ^{†††} Per one point increase in SOFA score

Figure 1: Mutational Analysis of Purpura Fulminans. (A) Schematic of the complement system. The complement system is broadly divided into two sub-pathways: humoral and opsonophagocytic. The humoral sub-pathway is comprised of soluble plasma proteins responsible for destroying microorganisms via formation of the membrane attack complex (MAC), which permeabilizes the surface

207 of the target cell. The opsonophagocytic sub-pathway is comprised of cellular receptors that recognize
 208 complement fragments deposited on microbial surfaces and facilitate phagocytosis and pathogen
 209 clearance. **(B)** Heterodimerization of integrin β_2 (B2) with integrin α_M (M) forms the anti-inflammatory
 210 signaling mediator complement receptor 3 (CR3) whereas heterodimerization of B2 with integrin α_X (X)
 211 forms the pro-inflammatory signaling mediator complement receptor 4 (CR4). **(C)** RVTT analyses
 212 comparing the European PF Cohort (PF) and the NHLBI ARDSnet iSPAAR cohort (Unselected Sepsis)
 213 in terms of ΔP variants (left panel), neutral missense variants (middle panel), and synonymous variants
 214 (right panel). **(D)** RVTT analyses comparing the two cohorts in terms of ΔP variants in the coagulation
 215 system (left panel) and glycolysis pathway (right panel).

Figure 2: Expression and ligand binding of the CR3 and CR4 variants. (A-B) Wild-type (WT) and mutant complement receptors were cloned and expressed in HEK-293T cells, and surface expression levels of CR3 (A) and CR4 (B) were evaluated by flow cytometry for integrin β_2 (ITGB2/CD18). WT CR3 and CR4 are depicted in black. Receptors containing a mutant integrin β_2 subunit are depicted in blue, those with a mutant integrin α_M (ITGAM) subunit are depicted in red, and those with a mutant integrin α_X (ITGAX) subunit are depicted in green. (C-D) The ability of receptor-expressing cells to bind immobilized iC3b was assessed in a solid-phase functional assay. iC3b binding activity of WT and mutant CR3 (C) and WT and mutant CR4 (D) are shown. ITGB2 P7Q, ITGAM R663W, ITGAM H687R, ITGAM T1001N, and ITGAX V1019M were predicted *in silico* to be benign. *P<0.05 compared to WT/WT control.

Figure 3: Signaling by the CR3 and CR4 variants. (A) TNF α -mediated activation of an NF- κ B dual luciferase reporter in cells expressing the PF-associated CR3 variants (left panel) or CR4 variants (right panel) in the presence or absence of the CR3/CR4 ligand iC3b. Control HEK-293T cells not expressing CR3 or CR4 (untransfected) and HEK-293T cells expressing wild-type or mutant CR3 or CR4 were used as negative and positive controls, respectively. Data are shown as the mean fluorescence intensity ratio of the iC3b-plus condition to the iC3b-minus condition. Error bars represent standard error of the mean. (B) PF-associated mutations in *ITGAM* (M*) reduce the ability of mutant CR3 (CR3*) to suppress inflammatory signaling. (C) PF-associated mutations in *ITGAX* (X*) enhance the ability of mutant CR4 (CR4*) to activate inflammatory signaling. (D) PF-associated mutations in the shared subunit *ITGB2*

235 (B2*) simultaneously decrease suppression of inflammatory signaling by CR3* and increase activation
236 of inflammatory signaling by CR4*.

237 References

- 238 1. Colling ME, Bendapudi PK. Purpura Fulminans: Mechanism and Management of Dysregulated
239 Hemostasis. *Transfusion medicine reviews* 2018;32(2):69-76. (In eng).
- 240 2. Lerolle N, Carlotti A, Melican K, et al. Assessment of the interplay between blood and skin vascular
241 abnormalities in adult purpura fulminans. *American journal of respiratory and critical care medicine*
242 2013;188(6):684-92. (In eng). DOI: 10.1164/rccm.201302-0228OC.
- 243 3. Povysil G, Petrovski S, Hostyk J, Aggarwal V, Allen AS, Goldstein DB. Rare-variant collapsing analyses for
244 complex traits: guidelines and applications. *Nature reviews Genetics* 2019;20(12):747-759. (In eng).
245 DOI: 10.1038/s41576-019-0177-4.
- 246 4. Lee S, Choi S, Kim YJ, Kim BJ, Hwang H, Park T. Pathway-based approach using hierarchical components
247 of collapsed rare variants. *Bioinformatics* 2016;32(17):i586-i594. (In eng). DOI:
248 10.1093/bioinformatics/btw425.
- 249 5. Richardson TG, Timpson NJ, Campbell C, Gaunt TR. A pathway-centric approach to rare variant
250 association analysis. *European journal of human genetics : EJHG* 2016;25(1):123-129. (In eng). DOI:
251 10.1038/ejhg.2016.113.
- 252 6. Kousi M, Söylemez O, Ozanturk A, et al. Evidence for secondary-variant genetic burden and non-
253 random distribution across biological modules in a recessive ciliopathy. *Nature genetics*
254 2020;52(11):1145-1150. (In eng). DOI: 10.1038/s41588-020-0707-1.
- 255 7. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. *Nat Rev Dis Primers* 2016;2:16037.
256 (In eng). DOI: 10.1038/nrdp.2016.37.
- 257 8. D'Urso S, Rajbhandari D, Peach E, et al. Septic Shock: A Genomewide Association Study and Polygenic
258 Risk Score Analysis. *Twin research and human genetics : the official journal of the International Society*
259 *for Twin Studies* 2020;23(4):204-213. (In eng). DOI: 10.1017/thg.2020.60.
- 260 9. Rautanen A, Mills TC, Gordon AC, et al. Genome-wide association study of survival from sepsis due to
261 pneumonia: an observational cohort study. *The Lancet Respiratory medicine* 2015;3(1):53-60. (In eng).
262 DOI: 10.1016/s2213-2600(14)70290-5.
- 263 10. Scherag A, Schöneweck F, Kesselmeier M, et al. Genetic Factors of the Disease Course after Sepsis: A
264 Genome-Wide Study for 28Day Mortality. *EBioMedicine* 2016;12:239-246. (In eng). DOI:
265 10.1016/j.ebiom.2016.08.043.
- 266 11. Srinivasan L, Page G, Kirpalani H, et al. Genome-wide association study of sepsis in extremely
267 premature infants. *Archives of disease in childhood Fetal and neonatal edition* 2017;102(5):F439-f445.
268 (In eng). DOI: 10.1136/archdischild-2016-311545.
- 269 12. Taudien S, Lausser L, Giamarellos-Bourboulis EJ, et al. Genetic Factors of the Disease Course After
270 Sepsis: Rare Deleterious Variants Are Predictive. *EBioMedicine* 2016;12:227-238. (In eng). DOI:
271 10.1016/j.ebiom.2016.08.037.
- 272 13. Bendapudi PK, Robbins A, LeBoeuf N, et al. Persistence of endothelial thrombomodulin in a patient
273 with infectious purpura fulminans treated with protein C concentrate. *Blood advances*
274 2018;2(21):2917-2921. (In eng). DOI: 10.1182/bloodadvances.2018024430.
- 275 14. Landsem A, Fure H, Krey Ludviksen J, et al. Complement component 5 does not interfere with
276 physiological hemostasis but is essential for Escherichia coli-induced coagulation accompanied by Toll-
277 like receptor 4. *Clinical and experimental immunology* 2019;196(1):97-110. (In eng). DOI:
278 10.1111/cei.13240.
- 279 15. Lappégard KT, Christiansen D, Pharo A, et al. Human genetic deficiencies reveal the roles of
280 complement in the inflammatory network: lessons from nature. *Proc Natl Acad Sci U S A*
281 2009;106(37):15861-6. (In eng). DOI: 10.1073/pnas.0903613106.
- 282 16. Janco RL, Morris P. Serum augments the generation of monocyte procoagulant stimulated by bacterial
283 lipopolysaccharide or chemotactic fragments of C5. *Thrombosis research* 1983;32(1):73-86. (In eng).
284 DOI: 10.1016/0049-3848(83)90156-1.

- 285 17. Lupu F, Keshari RS, Lambris JD, Coggeshall KM. Crosstalk between the coagulation and complement
286 systems in sepsis. *Thrombosis research* 2014;133 Suppl 1(0 1):S28-31. (In eng). DOI:
287 10.1016/j.thromres.2014.03.014.
- 288 18. Dustin ML. Complement Receptors in Myeloid Cell Adhesion and Phagocytosis. *Microbiology spectrum*
289 2016;4(6) (In eng). DOI: 10.1128/microbiolspec.MCHD-0034-2016.
- 290 19. Abram CL, Lowell CA. The ins and outs of leukocyte integrin signaling. *Annual review of immunology*
291 2009;27:339-62. (In eng). DOI: 10.1146/annurev.immunol.021908.132554.
- 292 20. Jawhara S, Pluskota E, Cao W, Plow EF, Soloviev DA. Distinct Effects of Integrins alphaXbeta2 and
293 alphaMbata2 on Leukocyte Subpopulations during Inflammation and Antimicrobial Responses.
294 *Infection and immunity* 2017;85(1):e00644-16. (In eng). DOI: 10.1128/iai.00644-16.
- 295 21. Dai S, Rajaram MV, Curry HM, Leander R, Schlesinger LS. Fine tuning inflammation at the front door:
296 macrophage complement receptor 3-mediates phagocytosis and immune suppression for *Francisella*
297 *tularensis*. *PLoS pathogens* 2013;9(1):e1003114. (In eng). DOI: 10.1371/journal.ppat.1003114.
- 298 22. Rosetti F, Mayadas TN. The many faces of Mac-1 in autoimmune disease. *Immunological reviews*
299 2016;269(1):175-93. (In eng). DOI: 10.1111/imr.12373.
- 300 23. Dellinger RP. Inflammation and coagulation: implications for the septic patient. *Clinical infectious*
301 *diseases : an official publication of the Infectious Diseases Society of America* 2003;36(10):1259-65. (In
302 eng). DOI: 10.1086/374835.
- 303 24. Levi M, van der Poll T. Coagulation and sepsis. *Thrombosis research* 2017;149:38-44. (In eng). DOI:
304 10.1016/j.thromres.2016.11.007.
- 305 25. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system.
306 *Cardiovasc Res* 2003;60(1):26-39. (In eng). DOI: 10.1016/s0008-6363(02)00857-x.
- 307 26. Price AL, Kryukov GV, de Bakker PI, et al. Pooled association tests for rare variants in exon-
308 resequencing studies. *Am J Hum Genet* 2010;86(6):832-8. (In eng). DOI: 10.1016/j.ajhg.2010.04.005.
- 309 27. Panarella M, Burkett KM. A Cautionary Note on the Effects of Population Stratification Under an
310 Extreme Phenotype Sampling Design. *Frontiers in genetics* 2019;10:398. (In eng). DOI:
311 10.3389/fgene.2019.00398.
- 312 28. Cochran WG. Some Methods for Strengthening the Common χ^2 Tests. *Biometrics* 1954;10(4):417-451.
- 313 29. Armitage P. Tests for Linear Trends in Proportions and Frequencies. *Biometrics* 1955;11(3):375-386.
314 DOI: 10.2307/3001775.
- 315 30. Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ
316 dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group
317 on "sepsis-related problems" of the European Society of Intensive Care Medicine. *Critical care*
318 *medicine* 1998;26(11):1793-800. (In eng). DOI: 10.1097/00003246-199811000-00016.
- 319 31. Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application
320 to analysis of sequence data. *Am J Hum Genet* 2008;83(3):311-21. (In eng). DOI:
321 10.1016/j.ajhg.2008.06.024.
- 322 32. Liu DJ, Leal SM. A novel adaptive method for the analysis of next-generation sequencing data to detect
323 complex trait associations with rare variants due to gene main effects and interactions. *PLoS genetics*
324 2010;6(10):e1001156. (In eng). DOI: 10.1371/journal.pgen.1001156.
- 325 33. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with
326 the sequence kernel association test. *Am J Hum Genet* 2011;89(1):82-93. (In eng). DOI:
327 10.1016/j.ajhg.2011.05.029.
- 328 34. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH. Tumor necrosis factor and interleukin-1
329 in the serum of children with severe infectious purpura. *The New England journal of medicine*
330 1988;319(7):397-400. (In eng). DOI: 10.1056/nejm198808183190703.

331